Welcome to Immunocore

immunocore

Immunocore is a privately owned biotechnology company focused on the development of engineered monoclonal T-cell Receptors (mTCRs) as the next evolutionary step after monoclonal antibodies.

Unlike conventional monoclonal antibodies, Immunocore’s mTCRs are not restricted to targeting cells via their membrane proteins. Instead, mTCRs use the power of the body’s own immune surveillance system, the T-Cell Receptor, as a means of targeting cells differentially expressing any protein, including intracellular ones. This platform technology opens up the ability of targeting cells based upon numerous known and well validated molecular targets unsuitable for monoclonal antibodies, thus removing a key bottleneck to the future development of effective biological therapeutics.

Immunocore is developing a broad platform of mTCR-based therapeutics for the treatment of a range of cancers, type I diabetes and HIV.

Latest News & Press

Dr Jonathan Knowles joins the Board

February 1st, 2010

PRESS RELEASE – Monday 1st February 2010 Immunocore Limited announces appointment of Dr Jonathan Knowles to the Board Company set to move into clinical development stage (Oxford, UK) 1st February 2010. Immunocore Limited, the Oxford-based pioneer of T cell receptor technology, announces the appointment of Dr Jonathan Knowles to the Board as a non-executive director [...]